home / stock / glaxf / glaxf news


GLAXF News and Press, GlaxoSmithKline Plc

Stock Information

Company Name: GlaxoSmithKline Plc
Stock Symbol: GLAXF
Market: OTC
Website: gsk.com

Menu

GLAXF GLAXF Quote GLAXF Short GLAXF News GLAXF Articles GLAXF Message Board
Get GLAXF Alerts

News, Short Squeeze, Breakout and More Instantly...

GLAXF - Dodge & Cox International Stock Fund Q2 2024 Shareholder Letter

2024-08-01 07:20:00 ET Summary After performing well in the first quarter of 2024, international equity markets appreciated modestly in the second quarter of 2024: the MSCI ACWI ex USA was up 1.0%. Our investment strategy focuses on finding attractively valued opportunities throug...

GLAXF - GSK Q2 Earnings Review: Vaccine Issues Aside, A Strong Quarter

2024-07-31 15:38:07 ET Summary UK-based Pharma giant GSK plc reported its Q2 earnings earlier today. GSK plc exceeded Q2 2024 expectations with revenue up 13%, operating profit up 18%, and EPS up 17%. GSK upgraded full-year guidance with 7-9% top-line growth forecasts, >10%...

GLAXF - GSK: Good Earnings Report, But Risks Ahead (Rating Downgrade)

2024-07-31 13:29:45 ET Summary GSK's H1 2024 earnings report is strong, with healthy sales growth, solid core EPS increase, and upgraded outlook, resulting in attractive market multiples. However, the outlook still indicates that investors need to brace for a weak H2 2024, with Ar...

GLAXF - GSK plc (GSK) Q2 2024 Earnings Call Transcript

2024-07-31 12:24:08 ET GSK plc (GSK) Q2 2024 Earnings Conference Call July 31, 2024, 07:00 ET Company Participants Nick Stone - Head, IR Emma Walmsley - CEO Tony Wood - Chief Scientific Officer Luke Miels - Chief Commercial Officer Deborah Waterhouse - CE...

GLAXF - Dodge & Cox Balanced Fund Q2 2024 Shareholder Letter

2024-07-27 09:50:00 ET Summary U.S. equity markets rose in Q2 2024, driven by positive earnings growth and expectations for interest rate cuts. Dodge & Cox Fund holds 48.1% in U.S. equities, 14.3% in non-U.S. equities, and 37.7% in fixed income securities plus cash. The fu...

GLAXF - Pfizer's Q2 Focus: Core Products And New Ventures

2024-07-25 15:30:25 ET Summary Analysts predict Pfizer's Q2 2024 revenue to be around $13 billion​. The EPS estimate for Q2 2024 is $0.22, reflecting challenges from decreased COVID-19 product demand. Investors are closely watching the performance of Pfizer's core produ...

GLAXF - Bullish On Vir Biotechnology's Innovative Pipeline That Targets HIV And Hepatitis

2024-07-17 16:47:26 ET Summary VIR develops medicines for infectious and viral diseases using proprietary platforms for monoclonal antibodies and T cell-based Viral Vectors. Positive Phase 2 trial results for chronic hepatitis delta highlight the company's potential to address unm...

GLAXF - 3 Undervalued Biotech Gems With 200%+ Analyst Price Targets

2024-07-04 10:01:38 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips One of the critical components of the investing world is the proliferation and understanding of analyst predictions. That’s because most retail investors prefer to research consumer info...

GLAXF - Amgen: You Haven't Seen Anything Yet

2024-06-17 11:30:03 ET Summary Amgen continues to delight investors with the growth in sales of its key blockbusters and the expansion of its portfolio of medications. In mid-June, Amgen pleased investors by announcing that the FDA had approved Blincyto to treat certain patients w...

GLAXF - ASCO 2024 Round-Up: Some Of The Most Impactful Cancer News Out Of The Big Meeting

2024-06-06 09:07:10 ET Summary AstraZeneca PLC showcased projects in two plenary lecture presentations at the Annual Meeting of the American Society of Clinical Oncology, or ASCO, including a trial that established osimertinib as the standard of care for EGFR-mutant NSCLC. Bristol...

Next 10